Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 May;2(3):175-87.
doi: 10.1177/1758834010361333.

Practical considerations in ovarian cancer chemotherapy

Mihaela Cristea  1 , Ernest Han, Lennie Salmon, Robert J Morgan
Affiliations

Practical considerations in ovarian cancer chemotherapy

Mihaela Cristea et al. Ther Adv Med Oncol. 2010 May.

Abstract

Epithelial ovarian cancer remains the most lethal gynecologic malignancy despite advances in treatment. The standard management generally involves a combination of surgical tumor debulking and chemotherapy. Over the decades, chemotherapy for ovarian cancer has evolved and currently involves a combination of intravenous platinum and taxane chemotherapy. Over the past decade, three randomized phase III trials have been reported, and all have demonstrated a significant survival advantage for intraperitoneal compared with intravenous chemotherapy. However, there are potential barriers and controversies related to the administration of intraperitoneal chemotherapy in ovarian cancer patients. In this review, we discuss the evolution and current management considerations of chemotherapy for the treatment of epithelial ovarian cancer.

Keywords: chemotherapy; intraperitoneal; ovarian cancer.

PubMed Disclaimer

References

    1. Aabo K., Adnitt P., Adams M., Alberts D.S., Barley V., Bell D.R., et al. (1991) Chemotherapy in advanced ovarian cancer: an overview of randomized clinical trials. BMJ 303: 884–893 - PMC - PubMed
    1. Alberts D.S., Green S., Hannigan E.V., O’Toole R., Stock-Novack D., Jolles C.J., et al. (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 10: 706–717 - PubMed
    1. Alberts D.S., Liu P.Y., Hannigan E.V., O’Toole R., Williams S.D., Young J.A., et al. (1996) Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. New Engl J Med 335: 1950–1955 - PubMed
    1. American Cancer Society (2009) Cancer Facts and Figures 2009. Atlanta: American Cancer Society
    1. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Burger R.A., et al. (2006) Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34–43 - PubMed

LinkOut - more resources